Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07474792 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
A Phase 2 study, sponsored by Oruka Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT07474792 is a Phase 2 study that is actively recruiting participants, run by Oruka Therapeutics. The registered enrollment target is 160 participants.
The verdict
NCT07474792, a Phase 2 study, is actively recruiting participants, sponsored by Oruka Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.
Interventions
- OTHER Placebo
- DRUG ORKA-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-03-19 |
| Est. Completion | 2029-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07474792
The ClinicalTrials.gov registry entry for NCT07474792 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oruka Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07474792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07474792 about?
NCT07474792 is a clinical study titled "Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis". This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.
What is the current status of trial NCT07474792?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2026-03-19. Estimated completion is 2029-04.
What interventions are being tested in trial NCT07474792?
The interventions under investigation include: Placebo (OTHER), ORKA-002 (DRUG).
Who is sponsoring clinical trial NCT07474792?
This trial is sponsored by Oruka Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.